NCT02689245 is a NA clinical trial of Tenofovir in Acute on Chronic Liver Failure, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT02689245?

NCT02689245 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT02689245?

Interventions in NCT02689245: Tenofovir, Fecal Microbiota Transplantation (FMT).

What condition does NCT02689245 study?

NCT02689245 studies Acute on Chronic Liver Failure.

Is NCT02689245 still recruiting?

NCT02689245 is currently completed. Last updated 23 November 2018.

Last reviewed 2018-11-23 · How we verify

NCT02689245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.

Completed NA Last updated 23 November 2018

What this trial tests

NA trial testing Tenofovir in Acute on Chronic Liver Failure in 64 participants. Completed in 13 March 2018.

Timeline

26 February 2016

Primary endpoint
13 March 2018

13 March 2018

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	64
Start date	26 February 2016
Primary completion	13 March 2018
Estimated completion	13 March 2018
Sites	1 location across India

Drugs / interventions tested

Tenofovir — full drug profile →
Fecal Microbiota Transplantation (FMT) — full drug profile →

Conditions studied

Acute on Chronic Liver Failure — all drugs for Acute on Chronic Liver Failure →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 80, any sex, with Acute on Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Data for stool microbiome will be collected for all the chronic hepatitis B subjects (pre cirrhotic,compensated,decompensated and reactivation). All the in and out patient with Hepatitis B reactivation will be recruited and randomized into two arms. Group 1 Tenofovir Group 2 Tenofovir with FMT (Fecal Microbiota Transplant). Tenofovir would be given 300 mg once daily FMT through NJ (Naso-Jejunal) tube for 7 days.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Gut microbiome, liver immunology, and liver diseases.
Wang R, Tang R, Li B, Ma X, et al · · 2021 · cited 297× · PMID 33318628 · DOI 10.1038/s41423-020-00592-6
Bringing microbiome-drug interaction research into the clinic.
Guthrie L, Kelly L. · · 2019 · cited 48× · PMID 31151933 · DOI 10.1016/j.ebiom.2019.05.009
Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.
Hou S, Yu J, Li Y, Zhao D, et al · · 2025 · cited 34× · PMID 40013938 · DOI 10.1002/advs.202413197
Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.
Sehgal R, Bedi O, Trehanpati N. · · 2020 · cited 34× · PMID 32850467 · DOI 10.3389/fcimb.2020.00341
Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.
Gu X, Lu Q, Zhang C, Tang Z, et al · · 2021 · cited 21× · PMID 34261137 · DOI 10.1055/s-0041-1732319
The role of faecal microbiota transplantation: looking beyond <i>Clostridioides difficile</i> infection.
D Goldenberg S, Merrick B, Merrick B. · · 2021 · cited 19× · PMID 33614028 · DOI 10.1177/2049936120981526
Gut microbiome and liver diseases.
Xu J, Chen N, Li Z, Liu Y. · · 2025 · cited 6× · PMID 40242515 · DOI 10.1016/j.fmre.2024.09.007

Verify or expand the search:

Other trials of Tenofovir

Trials testing the same drug.

NCT06295328 — From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients · Phase 1, PHASE2 · recruiting
NCT02650271 — Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC · Phase 3 · completed
NCT04539119 — Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA · Phase 3 · unknown
NCT04431375 — Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy · NA · unknown
NCT03986970 — The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention · Phase 2 · completed

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02689245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 23 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02689245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing